BAY 3630914 / Bayer - LARVOL DELTA

Bayer has cleared out four cancer candidates from its early-stage pipeline, including a STAT3 inhibitor acquired as part of its buyout of Vividion Therapeutics. (FierceBiotech) - "Vividion and Bayer 'made the strategic decision to discontinue the development' of VVD-130850 'based on the totality of the data, which includes safety, PK/PD and activity of the drug,'...The program consisted of a DGK-alpha inhibitor dubbed BAY 2862789 along with a DGKzeta Inhibitor called BAY 2965501....The final cancer drug thrown on the scrap heap was an anti-human CCR8 antibody called BAY 3375968 or lanerkitug."

Discontinued • P1 data • Colorectal Cancer • Melanoma • Ovarian Cancer • Renal Cell Carcinoma • Solid Tumor • Squamous Cell Carcinoma of Head and Neck • Triple Negative Breast Cancer

A First-in-Human (FIH) Study to Evaluate the Safety and Tolerability of VVD-130850 in Participants With Advanced Solid and Hematologic Tumors (clinicaltrials.gov) - P1 | N=125 | Active, not recruiting | Sponsor: Vividion Therapeutics, Inc. | Recruiting ➔ Active, not recruiting | N=280 ➔ 125 | Trial completion date: Dec 2027 ➔ Jan 2027 | Trial primary completion date: Dec 2027 ➔ Jan 2027

Checkpoint inhibition • Enrollment change • Enrollment closed • First-in-human • Trial completion date • Trial primary completion date • Hematological Disorders • Hematological Malignancies • Non Small Cell Lung Cancer • Oncology • Solid Tumor

A First-in-Human (FIH) Study to Evaluate the Safety and Tolerability of VVD-130850 in Participants With Advanced Solid and Hematologic Tumors (clinicaltrials.gov) - P1 | N=280 | Recruiting | Sponsor: Vividion Therapeutics, Inc. | N=200 ➔ 280

Enrollment change • Hematological Disorders • Hematological Malignancies • Non Small Cell Lung Cancer • Oncology • Solid Tumor

Vividion Therapeutics starts Phase I clinical trial in advanced solid and hematologic tumors with oral STAT3 inhibitor (Businesswire) - "Vividion Therapeutics...announced today that it has initiated dosing of patients in a Phase I clinical trial evaluating VVD-130850, an investigational oral STAT3 inhibitor for the treatment of advanced solid and hematologic tumors....The Phase I clinical trial will evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics and preliminary anti-tumor activity of VVD-130850 in patients with advanced solid and hematologic tumors as a single-agent and in combination with immune checkpoint inhibition."

Trial status • Hematological Malignancies • Solid Tumor

A First-in-Human (FIH) Study to Evaluate the Safety and Tolerability of VVD-130850 in Participants With Advanced Solid and Hematologic Tumors (clinicaltrials.gov) - P1 | N=160 | Recruiting | Sponsor: Vividion Therapeutics, Inc.

Checkpoint inhibition • Combination therapy • Metastases • New P1 trial • Hematological Disorders • Hematological Malignancies • Oncology • Solid Tumor